Example: bankruptcy
Clinical trials appendix Q1 2018 Results update
Ovarian cancer and other cancers 10 Lynparza(PARP inhibitor) Trial Population Patients Design Endpoints Status Phase III SOLO-2 NCT01874353 Platinum-sensitive recurrent
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Partnering for scientific leadership Biotech Unit ...
www.astrazeneca.comFor more information please go to: astrazeneca.com/Partnering Partnering for scientific leadership Biotech Unit Partnering Team Early-Stage opportunities (up to and including Phase I)
Condensed Consolidated Statement of Comprehensive …
www.astrazeneca.comconsolidated statement of comprehensive income, condensed consolidated statement of financial position, condensed consolidated statement of cash flows, condensed consolidated statement of changes in equity and Notes 1 to 5 and 7.
Farxiga’s DAPA-HF trial at ESC - astrazeneca.com
www.astrazeneca.comIn order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: this
Sustainability Report 2020 - AstraZeneca
www.astrazeneca.comThis is our sixth annual sustainability report, and it describes our progress and challenges from 1 January 2020 to 31 December 2020, unless otherwise stated. The content of this report is based on those sustainability focus areas deemed material through comprehensive stakeholder engagement and analysis. All our business operations
Pharmaceuticals in the Environment - AstraZeneca
www.astrazeneca.comPharmaceuticals in Drinking Water. WHO Press, Geneva, Switzerland. Link to report . 5 AstraZeneca is committed to ensuring the effective environmental management of our products across the whole of the product life cycle – from drug development and manufacture through to …
Clinical trials appendix Q3 2021 results update
www.astrazeneca.comPOSEIDON PD-L1+/-CTLA-4+SoC 1L NSCLC Imfinzi #+tremelimumab HIMALAYA L1+CTLA 4 1L HCC Lynparza#+Imfinzi# DuO E PARP+PD L1 1L endometrial cancer camizestrant+CDK4/6i SERENA-6 SERD+CDK4/6 1L HR+ HER2- ESR1m breast cancer capivasertib#+abiraterone CAPItello-281 AKT+abiraterone PTEN deficient metastatic hormone sensitive prostate cancer
Burnout Self-Test - AstraZeneca
www.astrazeneca.comIf you prefer rigorously validated tests, then the Maslach Burnout Inventory may be useful. This was developed by Christina Maslach, one of the leading researchers in the field of burnout. Copies can be purchased at this . site. Warning: Stress can cause severe health problems and, in extreme cases, death. While these stress
Managing Conflicting Priorities - AstraZeneca
www.astrazeneca.comconflicting priorities and for keeping everyone satisfied. When Priorities Clash You probably already know what happens when you have conflicting priorities. First of all, the quality of your work can suffer as you work more quickly or multitask, or you may find yourself delivering work later than you promised.
Sustainability Data Summary 2020 - AstraZeneca
www.astrazeneca.comthe report in the SDG column of the tables. Ethics and transparency15 Ethical business culture 15 Inclusion and diversity 17 Talent and workforce evolution 18 Workforce wellbeing and safety 19 Responsible supply chain 20 Human rights 22 Additional areas 23 Environmental protection6 Product environmental stewardship6 Greenhouse gas reduction 7
Full-year and Q4 2021 results
www.astrazeneca.comFeb 10, 2022 · In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter theGroup)provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group,
Related documents
NEW ZEALAND DATA SHEET - Medsafe
medsafe.govt.nzAvastin (bevacizumab) in combination with carboplatin and paclitaxel is indicated for the treatment of patients with recurrent, platinum-sensitive, epithelial ovarian, …
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eu3 Bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum -sensitive
Chemotherapy Sequencing Guide – For therapies …
sites.mckesson.comBevacizumab Bleomycin Carboplatin Cisplatin Cyclophosphamide Cytarabine Dacarbazine Docetaxel Doxorubicin Epirubicin Etoposide Fludarabine Fluorouracil Gemcitabine Ifosfamide Irinotecan Leucovorin Liposomal Oxaliplatin Methotrexate Mitomycin Paclitaxel Pemetrexed Pralatrexate Topotecan Vincristine Vinorelbine
Opdivo® (nivolumab) Injectable Medication …
www.aetna.comOpdivo ® (nivolumab) Injectable Medication Precertification Request . Page 3 of 3 (All fields must be completed and legible for Precertification Review.)
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.merck.com3 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE 1.1 Melanoma KEYTRUDA®(pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic ...